670253-38-0

Basic information

• Product Name: 6-AMino-4-chloro-3-pyridinecarbonitrile
• Synonyms: 6-AMino-4-chloro-3-pyridinecarbonitrile;6-amino-4-chloronicotinonitrile;3-Pyridinecarbonitrile, 6-amino-4-chloro-;EOS-61394
• CAS NO: 670253-38-0
• Molecular Formula: C₆H₄ClN₃
• Molecular Weight: 153.56906
• EINECS: -0
• Mol File: 670253-38-0.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 6-AMino-4-chloro-3-pyridinecarbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 6-AMino-4-chloro-3-pyridinecarbonitrile(670253-38-0)
• EPA Substance Registry System: 6-AMino-4-chloro-3-pyridinecarbonitrile(670253-38-0)

Safety Data

• Hazardous Substances Data: 670253-38-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Amino-4-chloro-3-pyridinecarbonitrile is used as an intermediate in the synthesis of pharmaceuticals for its ability to be incorporated into the molecular structures of various drugs. Its presence in the compound can contribute to the drug's efficacy and therapeutic properties.
Used in Agrochemical Industry:
6-Amino-4-chloro-3-pyridinecarbonitrile is also used as an intermediate in the synthesis of agrochemicals, where it can be a key component in the development of pesticides, herbicides, and other agricultural products. Its role in these compounds can enhance their effectiveness in protecting crops and managing pests.
Used in Organic Synthesis:
6-Amino-4-chloro-3-pyridinecarbonitrile serves as a valuable intermediate in organic synthesis, allowing chemists to create a wide range of compounds for various applications. Its versatility in reacting with other molecules makes it a useful component in the development of new chemical entities.
It is important to handle 6-Amino-4-chloro-3-pyridinecarbonitrile with care due to its potential hazardous properties, ensuring safety in its production, use, and disposal.

Upstream product

• 19798-80-2 2-Amino-4-chloropyridine 
• 557-21-1 zinc(II) cyanide 
• 670253-37-9 4-chloro-5-iodopyridin-2-ylamine 
• 942947-94-6 5-bromo-4-chloro-pyridin-2-ylamine 
• 557-21-1 dicyanozinc 

Downstream Products

• 670253-32-4 5-(2-amino-5-cyanopyridin-4-ylamino)indole-1-carboxylic acid phenylamide 
• 1445153-74-1 6-amino-N-(3-methylphenyl)-4-[(3-methylphenyl)amino]pyridine-3-carboxamide 
• 1445151-14-3 6-(3-ethylureido)-N-m-tolyl-4-(m-tolylamino)nicotinamide 
• 1708975-10-3 6-amino-4-((2-methoxyethyl)amino)nicotinonitrile 
• 1621000-13-2 6-amino-4-phenylniconitrile 

Relevant articles and documents

THERAPEUTIC COMPOUNDS AND METHODS OF USE

The invention relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

High-selectivity fibroblast growth factor receptor inhibitor and application

The invention discloses a high-selectivity fibroblast growth factor receptor inhibitor and application, and particularly relates to a compound shown in a formula (I) or a pharmaceutically acceptable salt, a solvate, a geometric isomer, a stereoisomer, a tautomer and any mixture thereof. The compound shown in the formula (I) or the pharmaceutically acceptable salt, the solvate and the pharmaceutical composition thereof can be applied to prevention or treatment of diseases related to FGFR4 activity or overexpression, and can also be combined with other medicines to be used for treating various related diseases, especially for treating various cancers, wherein the cancers may be liver cancer, lung cancer, gastric cancer, breast cancer, ovarian cancer, prostate cancer, renal cell carcinoma, skin cancer, colon cancer, bile duct cancer, glioma or sarcoma.

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity, resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the optimization of a series of amidopyridines (from compound 2), focusing on properties suitable for achieving short target engagement after intravenous administration. By increasing potency and human metabolic clearance, we identified compound 24, a potent and selective CDK9 inhibitor with suitable predicted human pharmacokinetic properties to deliver transient inhibition of CDK9. Furthermore, the solubility of 24 was considered adequate to allow i.v. formulation at the anticipated effective dose. Short-term treatment with compound 24 led to a rapid dose- and time-dependent decrease of pSer2-RNAP2 and Mcl-1, resulting in cell apoptosis in multiple hematological cancer cell lines. Intermittent dosing of compound 24 demonstrated efficacy in xenograft models derived from multiple hematological tumors. Compound 24 is currently in clinical trials for the treatment of hematological malignancies.

Halogen acid salt product of urea compound, and preparation method thereof

The invention particularly relates to a salt of a urea compound, and a preparation method thereof. According to the method, an organic solvent and water mixed crystallization solvent system is adopted, an free alkali and an acid are paired to form ion pairs, crystallization is conducted, and then heat preservation pulping crystallization is conducted within a certain temperature range to obtain the novel crystal form, wherein the product is high in solubility in water, simple in preparation method, high in yield, stable in property and easy to store, transport and use in the later period. Thepreparation method provided by the invention is good in process reproducibility, simple to operate and suitable for industrial production.

Novel crystal form product of urea compound, and preparation method thereof

The invention particularly relates to a novel crystal form of a urea compound, and a preparation method thereof. According to the method, an organic solvent crystallization solvent system is adopted,an free alkali and an acid are paired to form ion pairs, crystallization is conducted, and then heat preservation pulping crystallization is conducted within a certain temperature range to obtain thenovel crystal form, wherein the crystal form product is high in water solubility, simple in preparation method, high in yield, stable in property and easy to store, transport and use in the later period. The preparation method provided by the invention is good in process reproducibility, simple to operate and suitable for industrial production.

Malate product of urea compound, and preparation method thereof

The invention particularly relates to a salt of a urea compound, and a preparation method thereof. According to the method, an organic solvent and water mixed crystallization solvent system is adopted, an free alkali and an acid are paired to form ion pairs, crystallization is conducted, and then heat preservation pulping crystallization is conducted within a certain temperature range to the novelcrystal form, wherein the product is high in solubility in water, simple in preparation method, high in yield, stable in property and easy to store, transport and use in the later period. The preparation method provided by the invention is good in process reproducibility, simple to operate and suitable for industrial production.

A class of intermediates for preparing anticancer drugs

The invention discloses a raw material for synthesizing an anticancer drug, and a key intermediate for synthesizing an anticancer drug. The invention further discloses a preparation method of an anticancer drug. According to the present invention, the syn

COMPOUND FOR SELECTIVELY INHIBITING KINASE AND USE THEREOF

Provided are a compound of formula (I), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, use thereof as a selective inhibitor for FGFR4 kinase and use thereof in manufacturing a medicament or pharmaceutical composition for treating diseases due to FGFR4 or FGF19. The compound disclosed by the invention has selective and significant inhibitory activities against FGFR4, and has wide application prospect in the field of tumor treatment.

Chemical Compounds

Provided are a series of novel pyridine or pyrimidine derivatives which inhibit CDK9 and may be useful for the treatment of hyperproliferative diseases. In particular the compounds are of use in the treatment of proliferative disease such as cancer including hematological malignancies such as acute myeloid leukemia, multiple myeloma, chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt's lymphoma, follicular lymphoma and solid tumors such as breast cancer, lung cancer, neuroblastoma and colon cancer.

Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors

The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.